Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The AASLD/IDSA guidelines recommend that all children with chronic HCV infection who are 3 years of age or older should receive treatment with an approved DAA regimen, regardless of disease severity[AASLD-IDSA HCV]
  • Glecaprevir/pibrentasvir is the first choice for adolescent treatment of HCV and is approved for adolescents aged 12-17 years with any HCV genotype
  • Ledipasvir/sofosbuvir and sofosbuvir plus ribavirin are approved by the FDA for the treatment of HCV infection in patients 3 years of age and older

    Action required